A digital health app designed to track and report on patient perceived pain relief and general well-being associated with spinal cord stimulation (SCS) or dorsal root ganglion (DRG) therapy will be made available soon by Abbott.
NeuroSphere™ myPath™ allows patients to record pain outcomes during the device trial period prior to permanent implantation of a neuromodulation device. Patients will be able to share information collected in the app with health care providers to provide a comprehensive assessment of the SCS or DRG therapy. The app also includes access to educational resources and connection to Abbott support.
The digital health app will be compatible with Abbott’s Proclaim XR SCS System for patients with chronic pain in the trunk and limbs, as well as the Proclaim DRG Neurostimulation System for patients with chronic pain in the lower limbs caused by complex regional pain syndrome or causalgia.
“The launch of the NeuroSphere myPath is one more example of how Abbott has been leading the way in providing remote ways to connect doctors and patients,” said Keith Boettiger, vice president, Neuromodulation, Abbott. “Patients will be able to see information on their phone that would typically only be accessible in a doctor’s office – helping patients to share their journey with their doctors.”
NeuroSphere myPath will be available on the Apple App Store in the coming weeks and is expected to be available on Android devices in the second quarter of 2021.
For more information visit abbott.com.
Abbott to launch the NeuroSphere™ myPath™ digital health app designed to track and report pain relief in chronic pain patients with physicians prior to device implant. [press release]. Abbott Park, IL: Abbott; January 14, 2021.
This article originally appeared on Clinical Pain Advisor